ABSTRACT
Objectives:
It is suggested that drug eluting stents (DES) may have systemic anti-inflammatory properties and this can play a role in decreased restenosis rates. We aimed to compare bare metal stents (BMS) and DES for their effects on C-reactive protein (CRP) levels, a good marker of systemic inflammation. We also aimed to investigate the relationship between the inflammation levels and myonecrosis and adverse cardiac events.
Materials and Methods:
Patients undergoing elective stent implantation were grouped as BMS (n=70) and DES (n=42). Basal and 24th hour postprocedural CRP and creatine kinase-MB (CK-MB) levels were measured and the difference (delta=Δ) was compared between the groups. The patients were followed up for adverse cardiac events for one year.
Results:
The mean age was 62±11 years and 75% were males. There was significant CRP rise in both groups at the 24th hour, but the ΔCRP was 2.1 (0.5-6.2) mg/L in the BMS group and 2.3 (0.2-5.2) mg/L in the DES group, the difference was not statistically significant (p=0.703). ΔCK-MB and adverse cardiac event rates were similar between the two groups (p=0.897 and p=0.785). There was no correlation between ΔCRP and ΔCK-MB (r=-0.090 and p=0.459 for BMS, r=0.158 and p=0.318 for DES). The effect of ΔCRP on the incidence of adverse cardiac events was not significant (p=0.349 for BMS, p=0.135 for DES).
Conclusion:
Our findings reveal that patients with BMS and DES implantation exhibit similar grade of systemic inflammation after the procedure. At similar levels of systemic inflammation, the local anti-inflammatory properties of DES can play a role at decreased restenosis rates.
Keywords:
Bare Metal Stent, Drug Eluting Stent, CRP, Inflammation
References
1Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol. 1999;10:499-506.
2Welt FG, Tso C, Edelman ER, et al. Leukocyte recruitment and expression of chemokines following different forms of vascular injury. Vasc Med. 2003;8:1-7.
3Pepys MB. The acute phase response and C-reactive protein. Ledingham JGG, Waeatherall DJ, Warrel DA, editors. Oxford textbook of medicine, Oxford University Press: New York. 1995. p: 1527-1533.
4Versaci F, Gaspardone A. Prevention of restenosis after stenting: the emerging role of inflammation. Coron Artery Dis. 2004;15:307-311.
5Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol. 1998;82:515-518.
6Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106:1867-1873.
7Kim JY, Ko YG, Shim CY, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol. 2005;96:1384-1388.
8Gogo PB, Jr., Schneider DJ, Watkins MW, et al. Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis. 2005;19:87-92.
9Dibra A, Ndrepepa G, Mehilli J, et al. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus eluting versus bare metal stents. Am J Cardiol. 2005;95:1238-1240.
10Liu J, Zhuo XZ, Liu W, et al. Drug-eluting stent, but not bare metal stent, accentuates the systematic inflammatory response in patients. Cardiology. 2014;128:259-265.
11Ryan TJ, Bauman WB, Kennedy JW, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 1993;88:2987-3007.
12Azar RR, McKay RG, Kiernan FJ, et al. Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol. 1997;80:1476-1478.
13Klitkou J, Jensen LO, Hansen HS, et al. High sensitive C-reactive protein and interleukin 6 are not related to neointimal hyperplasia in paclitaxel eluting stents or bare metal stents. An intravascular ultrasound study. Int J Cardiol. 2007;119:114-116.
14Gaspardone A, Versaci F, Tomai F, et al. C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol. 2006;97:1311-1316.
15Karha J, Bavry AA, Rajagopal V, et al. Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimuseluting stent. Am J Cardiol. 2006;98:616-618.
16Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175-181.
17Kounis NG, Hahalis G, Theoharides TC. Coronary stents, hypersensitivity reactions, and the Kounis syndrome. J Interv Cardiol. 2007;20:314-323.
18Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
19Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006;24:33-50.
20Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003;107:1750-1756.
21Klein LW, Kramer BL, Howard E, et al. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol. 1991;17:621-626.
22Ravkilde J, Nissen H, Mickley H, et al. Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. Am Heart J. 1994;127:13-20.
23Hill RA, Boland A, Dickson R, et al. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess. 2007;11:iii, xi-221.
